Purple Biotech company info

What does Purple Biotech do?
Purple Biotech (TLV:PPBT), (NASDAQ:PPBT) is a biotechnology company focused on advancing various cancer therapies that target the challenges of resistance to treatments. With a pipeline that includes development-stage drugs aimed at providing new options for cancer patients, Purple Biotech's projects predominantly revolve around creating innovative, targeted therapies. The company's objective is to improve patient outcomes by exploring pathways and mechanisms that can overcome tumor resistance and reduce side effects, making cancer treatments more effective and tolerable. Purple Biotech is solely listed on the NASDAQ stock exchange under the symbol PPBT, highlighting its commitment to research and development in the oncology sector.
Purple Biotech company media
Company Snapshot

Is Purple Biotech a public or private company?

key
Ownership
Public

How many people does Purple Biotech employ?

people
Employees
20

What sector is Purple Biotech in?

pie chart
Sector
Health Care

Where is the head office for Purple Biotech?

location pin
Head Office
Tel Aviv, Israel

What year was Purple Biotech founded?

founded flag
Year Founded
1968
What does Purple Biotech specialise in?
/Cancer Therapeutics /Medical Research /Drug Development /Clinical Trials /Acquired Resistance /Pharmacological Services

What are the products and/or services of Purple Biotech?

Overview of Purple Biotech offerings
NT219, a small molecule targeting treatment-resistant cancer pathways.
CM24, a monoclonal antibody inhibiting CEACAM1 for various cancers.
Research partnership for developing novel cancer therapies.
Collaboration on drug discovery and development in oncology.
Involvement in early-stage research on tumor microenvironment targeted therapies.
Expertise in kinase inhibitor technology for cancer treatment.

Who is in the executive team of Purple Biotech?

Purple Biotech leadership team
  • Mr. Gil  Efron CPA, M.A.
    Mr. Gil Efron CPA, M.A.
    Chief Executive Officer
  • Dr. Michael  Schickler Ph.D.
    Dr. Michael Schickler Ph.D.
    Head of Clinical & Regulatory Affairs
  • Mr. Lior  Fhima CPA, M.B.A.
    Mr. Lior Fhima CPA, M.B.A.
    Chief Financial Officer
  • Mr. Ido  Morpurgo B.Sc., L.L.M.
    Mr. Ido Morpurgo B.Sc., L.L.M.
    Vice President of Operations